Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.48 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1920437 | 0.89 | CYP1A2 (0.61) | ALDH1A1HSD17B10CYP1B1HIF1ACYP2A6 | |
| SCHEMBL69325 | 0.79 | CES2 (0.43) | ALDH1A1HSD17B10CYP1B1CYP2A6TDP1 | |
| SCHEMBL1343465 | 0.78 | CA1 (0.69) | ALDH1A1HSD17B10CYP1B1HIF1ACYP2A6 | |
| SCHEMBL29245731 | 0.78 | CYP1B1 (0.56) | ALDH1A1HSD17B10CYP1B1HIF1ACYP2A6 | |
| SCHEMBL9098387 | 0.78 | ALDH1A1 (0.50) | ALDH1A1HSD17B10CYP1B1TSHRTDP1 | |
| SCHEMBL476027 | 0.78 | CTDSP1 (0.53) | ALDH1A1HSD17B10TSHRTDP1CYP1A2 | |
| SCHEMBL5381544 | 0.78 | MEN1 (0.39) | CYP1B1CYP1A2CA1CA2CYP1A1 | |
| SCHEMBL1921032 | 0.77 | ALDH1A1 (0.44) | ALDH1A1HSD17B10CYP1B1HIF1ACYP2A6 | |
| SCHEMBL3632654 | 0.75 | CA1 (0.65) | ALDH1A1HSD17B10CYP1B1HIF1ACYP2A6 | |
| SCHEMBL9671450 | 0.75 | GABRA1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116813979-A | Nucleating agent, synthetic resin composition containing same, and molded article thereof | 株式会社ADEKA | 2023-09-29 | — | — | CN | disclosed |
| CN-112839988-B | Nucleating agent, synthetic resin composition containing same, and molded article thereof | 株式会社ADEKA | 2023-06-06 | — | — | CN | disclosed |
| US-20210395209-A1 | NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF | ADEKA CORPORATION (JP) | 2021-12-23 | — | — | US | disclosed |
| EP-3858909-A1 | NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF | ADEKA CORPORATION (JP) | 2021-08-04 | — | — | EP | disclosed |
| CN-112839988-A | Nucleating agent, synthetic resin composition containing same, and molded article thereof | 株式会社ADEKA | 2021-05-25 | — | — | CN | disclosed |
| WO-2020067144-A1 | NUCLEATING AGNET, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF | 株式会社ADEKA | 2020-04-02 | — | — | WO | disclosed |
| US-8394974-B2 | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-03-12 | — | — | US | disclosed |
| EP-1718629-B1 | Benzopyran compounds useful for the treatment of arrhytmia | NISSAN CHEMICAL IND LTD (JP) | 2012-12-26 | — | — | EP | disclosed |
| US-7964623-B2 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| EP-1590491-B1 | ADDUCTS BASED ON CYCLIC COMPOUNDS AND THE USE THEREOF AS TANNING AGENTS AND CURING AGENTS | BASF SE (DE) | 2011-06-01 | — | — | EP | disclosed |
| US-20060101583-A1 | Adducts based on cyclic compounds and the use thereof as tanning agents and curing agents | BASF AKTIENGESELLSCHAFT (DE) | 2006-05-18 | — | — | US | disclosed |
| US-20060053564-A1 | Tanning agents and preservatives | BASF AKTIENGESELLSCHAFT (DE) | 2006-03-16 | — | — | US | disclosed |
| US-20050282730-A1 | Thrombopoetin receptor activator and process for producing the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
| EP-1590491-A1 | ADDUCTS BASED ON CYCLIC COMPOUNDS AND THE USE THEREOF AS TANNING AGENTS AND CURING AGENTS | BASF Aktiengesellschaft (DE) | 2005-11-02 | — | — | EP | disclosed |
| EP-1590492-A1 | TANNING AGENTS AND PRESERVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2005-11-02 | — | — | EP | disclosed |
| WO-2005090357-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-29 | — | — | WO | disclosed |
| EP-1552828-A1 | THROMBOPOETIN RECEPTOR ACTIVATOR AND PROCESS FOR PRODUCING THE SAME | Nissan Chemical Industries, Ltd. (JP) | 2005-07-13 | — | — | EP | disclosed |
| WO-2005031007-A1 | METHOD FOR THE PRODUCTION OF LEATHER AND SEMIFINISHED PRODUCTS, AND FORMULATIONS THAT ARE SUITABLE THEREFOR | BASF AKTIENGESELLSCHAFT (DE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2004067782-A1 | TANNING AGENTS AND PRESERVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2004-08-12 | — | — | WO | disclosed |
| WO-2004067781-A1 | ADDUCTS BASED ON CYCLIC COMPOUNDS AND THE USE THEREOF AS TANNING AGENTS AND CURING AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395209-A1 | NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF | NOC2L, RIF1, NAP1L1 | ALDH1A1 2699/4885HSD17B10 3823/4885CYP1B1 2753/4885 |
| US-20050282730-A1 | Thrombopoetin receptor activator and process for producing the same | PDGFRA, PTAFR, TBXA2R | ALDH1A1 2034/4885HSD17B10 1809/4885CYP1B1 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.